Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and voluntarily sign an informed consent form~* Age \> 18 years at the time of signing the informed consent form~* Pathological confirmation of leukemia or myelodysplastic syndrome.~* AML according to WHO criteria; except for core-binding factor AMLs (t(8;21), inv(16) or t(16;16)) and APL~* ALL~* MDS~* Patients with AML include the following:~* Patients in 2nd or greater relapse~* Patients in first relapse with initial CR duration lasting \<6 months~* Patients in first relapse refractory to induction therapy~* Patients with primary refractory AML~* Patients with ALL include the following~* Patients with T-cell ALL refractory or in relapse following nelarabine~* Patients with other ALL that is refractory or in relapse.~* Patients with MDS include the following:~* The subset of RAEB-2 patients with \>10% blasts with at least 1 prior therapy that includes a hypomethylating agent.~* Previously untreated chemotherapy induced AML~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1 or 2~* Able to adhere to the study visit schedule and other protocol requirements~* Life expectancy of at least 12 weeks~* Laboratory values fulfilling the following:~* Serum creatinine \< 1.5 mg/dL~* Serum total bilirubin \< 1.5 mg/dL~* Serum alanine aminotransferase or aspartate aminotransferase \< 150 IU/liter Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.~* Cardiac ejection fraction \> 50% by MUGA scan or echocardiography~* All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the patient from signing the informed consent form~* Chemotherapy or other investigational anticancer therapeutic drugs in the two weeks prior to study entry; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to 24 hours before study entry~* Clinical evidence of active CNS leukemic involvement~* Pregnant or lactating women~* Clinically significant cardiac disease (New York Heart Association Class III or IV)~* Severe debilitating pulmonary disease~* Active and uncontrolled infection. Patients with an infection under active treatment with antibiotics and whose infection is controlled may be entered into the study~* Current evidence of invasive fungal infection (blood or tissue culture); HIV or hepatitis C infection~* Hypersensitivity to cytarabine, daunorubicin or liposomal products~* History of Wilson's disease or other copper-related disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).